| 摘要 |
One or more cannabinoids selected from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV) for use in the treatment of an inflammatory skin disease is provided. The inflammatory skin disease is preferably selected from a microbial infection-induced dermatitis, a solar dermatitis or an atopic dermatitis. The cannabinoid may be in the form of a highly purified extract of cannabis such that it is present at greater than 95% of the total extract (w/w), or it may be synthetically produced. Preferably the cannabinoid is used at a dose of between and 10 and 1000mg and may be administered concomitantly with one or more medicaments, in particular corticosteroids. |
